A lab-made brain compound from the racetam family, developed in Japan in the 1990s for the mental after-effects of stroke and dementia but never sold as a medicine. The strongest human signal is reduced low motivation after stroke; broad memory or longevity benefits are not established, and long-term safety is unknown. (Full Review)

Protocol

Dose

150–900 mg/day

Trials used 600–900 mg/day; positive apathy signal only at 900 mg/day. Community use starts low and titrates upward.

Frequency

2–3× daily

Short 3–5 hour half-life favors split dosing to maintain steady levels rather than a single daily dose.

Timing

Daytime

Morning and early afternoon preferred; late-evening dosing usually avoided to prevent sleep disruption. Food delays absorption without changing exposure.

Time to effect

Motivation / apathy

Weeks

Trial benefit was assessed over weeks, so meaningful effects, if real, likely require sustained use.

Cognitive benefit

Sustained use

Any cognitive or motivational benefit likely requires sustained use rather than a single dose.

Acute focus / calm

Within hours

Acute subjective effects are reported by users within hours of dosing, consistent with rapid absorption.

Benefits

Medium: Reduction of post-stroke apathy

Low: Cognition and memory enhancement; neuroprotection

Speculative: Mood support and anxiety reduction; general longevity or healthspan extension

Contraindications

Pregnancy or breastfeeding

Children and adolescents

Active seizure disorders

Inability to obtain a verified-purity product

Key Interactions

Cholinergic drugs and supplements (cholinesterase inhibitors such as donepezil, rivastigmine; choline sources such as alpha-GPC, citicoline)

Other racetams (piracetam, aniracetam, oxiracetam) and choline-containing nootropics

GABAergic and sedative agents (benzodiazepines such as diazepam, alcohol, sedating antihistamines)

NMDA-active drugs (memantine, ketamine, dextromethorphan)

Anti-seizure medications

Risk & Side Effects

Medium: Unknown long-term human safety

Low: Testicular toxicity; common nuisance side effects

Speculative: Excitotoxicity from NMDA/calcium modulation; seizure-threshold effects

Monitoring

Marker	Target	Why
ALT	10–26 U/L	Screens liver cell stress from a heavily metabolized compound
AST	10–26 U/L	Complements ALT for liver injury
Total testosterone (males)	500–900 ng/dL	Documents gonadal function given the animal testicular signal
CBC	Within standard normal limits	General safety screen for an unregulated product

Cadence: Baseline before starting, then at roughly 4–8 weeks and every 6–12 months during continued use

Qualitative Assessment

Motivation and drive — note whether apathy or initiative changes
Subjective focus and mental clarity, and any brain fog
Mood and anxiety level, including any irritability
Sleep quality and onset, especially if dosing later in the day
Headache or gastrointestinal symptoms as tolerance signals

Nefiracetam for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment